I. Les-micro-arnsmiarns and ). , 35 IV.I Rôle et mode d'action des miARNs, p.35

I. Etude-immunohistochimique-de-hur, K. Hur, and M. , 49 III.1, p.49

. En-analyse-bivariée, le nombre de cellules marquées par l'anticorps anti-MCM6 a un impact négatif significatif sur la survie (p<0 ,01) (tableau 5) Il n'y a pas de corrélation en analyse multivariée, pp.71-77

. En-analyse-bivariée, le nombre de cellules marquées par l'anticorps anti-Ki67 a un impact négatif significatif sur la survie (p<0,01) (tableau 5) Cette corrélation est également retrouvée en analyse multivariée (p<0, pp.1-6

E. Quoix and E. Lemarié, ??pid??miologie du cancer bronchique primitif??: aspects classiques et nouveaut??s, Revue des Maladies Respiratoires, vol.28, issue.8, pp.1048-1058, 2011.
DOI : 10.1016/j.rmr.2010.12.015

A. Belot, P. Grosclaude, N. Bossard, E. Jougla, E. Benhamou et al., Cancer incidence and mortality in France over the period Revue d'Épidémiologie et de Santé Publique, juin, vol.56, issue.3, pp.159-175, 1980.

W. Travis, E. Brambilla, M. Noguchi, A. Nicholson, K. Geisinger et al., International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-285, 2011.
DOI : 10.1097/JTO.0b013e318206a221

URL : https://hal.archives-ouvertes.fr/inserm-00561753

F. Detterbeck, D. Boffa, and L. Tanoue, The New Lung Cancer Staging System, Chest, vol.136, issue.1, pp.260-271, 2009.
DOI : 10.1378/chest.08-0978

K. Kadota, K. Suzuki, S. Kachala, E. Zabor, C. Sima et al., A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma, Modern Pathology, vol.24, issue.8, pp.1117-1127, 2012.
DOI : 10.1200/JCO.2008.16.4855

P. Russell, Z. Wainer, G. Wright, M. Daniels, M. Conron et al., Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification, Journal of Thoracic Oncology, vol.6, issue.9, pp.1496-1504, 2011.
DOI : 10.1097/JTO.0b013e318221f701

A. Warth, T. Muley, M. Meister, A. Stenzinger, M. Thomas et al., The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival, Journal of Clinical Oncology, vol.30, issue.13, pp.1438-1446, 2012.
DOI : 10.1200/JCO.2011.37.2185

T. Woo, K. Okudela, H. Mitsui, M. Tajiri, T. Yamamoto et al., Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases, Pathology International, vol.3, issue.12, pp.785-791, 2012.
DOI : 10.1097/PAS.0b013e3181c79a6f

A. Yoshizawa, N. Motoi, G. Riely, C. Sima, W. Gerald et al., Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases, Modern Pathology, vol.57, issue.5, pp.653-664, 2011.
DOI : 10.1002/1097-0142(19860415)57:8<1555::AID-CNCR2820570820>3.0.CO;2-N

W. Ma and H. Furneaux, Localization of the human HuR gene to chromosome 19p13. 2. Human genetics, pp.32-35, 1996.

W. Ma, S. Cheng, C. Campbell, A. Wright, and H. Furneaux, Cloning and Characterization of HuR, a Ubiquitously Expressed Elav-like Protein, Journal of Biological Chemistry, vol.269, issue.14, pp.8144-8151, 1996.
DOI : 10.1073/pnas.89.4.1296

C. Maris, C. Dominguez, and F. Allain, The RNA recognition motif, a plastic RNA-binding platform to regulate post-transcriptional gene expression, FEBS Journal, vol.50, issue.5, pp.2118-2149, 2005.
DOI : 10.1128/MCB.7.5.1731

D. Kenan, C. Query, and J. Keene, RNA recognition: towards identifying determinants of specificity, Trends in Biochemical Sciences, vol.16, issue.6, pp.214-220, 1991.
DOI : 10.1016/0968-0004(91)90088-D

C. Chen and A. Shyu, AU-rich elements: characterization and importance in mRNA degradation, Trends in Biochemical Sciences, vol.20, issue.11, pp.465-470, 1995.
DOI : 10.1016/S0968-0004(00)89102-1

V. Myer, X. Fan, and J. Steitz, Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay, The EMBO Journal, vol.16, issue.8, pp.2130-2139, 1997.
DOI : 10.1093/emboj/16.8.2130

M. Hinman and H. Lou, Diverse molecular functions of Hu proteins, Cellular and Molecular Life Sciences, vol.65, issue.20, pp.3168-3181, 2008.
DOI : 10.1007/s00018-008-8252-6

X. Fan and J. Steitz, HNS, a nuclear-cytoplasmic shuttling sequence in HuR, Proceedings of the National Academy of Sciences, vol.18, issue.7, pp.15293-15298, 1998.
DOI : 10.1128/MCB.18.7.4141

A. Doller, J. Pfeilschifter, and W. Eberhardt, Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR, Cellular Signalling, vol.20, issue.12, pp.2165-73, 2008.
DOI : 10.1016/j.cellsig.2008.05.007

H. Li, Lipopolysaccharide-induced Methylation of HuR, an mRNA-stabilizing Protein, by CARM1, Journal of Biological Chemistry, vol.13, issue.47, pp.44623-44630, 2002.
DOI : 10.1128/MCB.20.13.4765-4772.2000

I. López-de-silanes, A. Lal, and M. Gorospe, HuR: Post-Transcriptional Paths to Malignancy, RNA Biology, vol.2, issue.1, pp.11-13, 2005.
DOI : 10.4161/rna.2.1.1552

I. López-de-silanes, J. Fan, X. Yang, A. Zonderman, O. Potapova et al., Role of the RNA-binding protein HuR in colon carcinogenesis, Oncogene, vol.22, issue.46, pp.7146-7154, 2003.
DOI : 10.1073/pnas.97.26.14085

M. Heinonen, P. Bono, K. Narko, S. Chang, J. Lundin et al., Cytoplasmic HuR Expression Is a Prognostic Factor in Invasive Ductal Breast Carcinoma, Cancer Research, vol.65, issue.6, pp.2157-2161, 2005.
DOI : 10.1158/0008-5472.CAN-04-3765

C. Denkert, W. Weichert, K. Winzer, B. Müller, A. Noske et al., Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma, Clinical Cancer Research, vol.10, issue.16, pp.5580-5586, 2004.
DOI : 10.1158/1078-0432.CCR-04-0070

C. Denkert, W. Weichert, S. Pest, I. Koch, D. Licht et al., Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression, Cancer Research, vol.64, issue.1, pp.189-195, 2004.
DOI : 10.1158/0008-5472.CAN-03-1987

D. Stoppoloni, I. Cardillo, A. Verdina, B. Vincenzi, S. Menegozzo et al., Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma, Cancer, vol.352, issue.10, pp.2761-2769, 2008.
DOI : 10.4161/rna.2.1.1552

S. Niesporek, G. Kristiansen, A. Thoma, W. Weichert, A. Noske et al., Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression, International Journal of Oncology, vol.32, issue.2, pp.341-347, 2008.
DOI : 10.3892/ijo.32.2.341

N. Cho, H. Han, Y. Soh, K. Lee, and H. Son, Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas, Pathology, vol.39, issue.6, pp.545-550, 2007.
DOI : 10.1080/00313020701684391

X. Yi, Y. Zhou, W. Zheng, and S. Chambers, HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer, Australian and New Zealand Journal of Obstetrics and Gynaecology, vol.26, issue.1, pp.93-98, 2009.
DOI : 10.1111/j.1479-828X.2008.00937.x

M. Vázquez-chantada, D. Fernández-ramos, N. Embade, N. Martínez-lopez, M. Varela-rey et al., HuR/Methyl-HuR and AUF1 Regulate the MAT Expressed During Liver Proliferation, Differentiation, and Carcinogenesis, Gastroenterology, vol.138, issue.5, 1943.
DOI : 10.1053/j.gastro.2010.01.032

B. Blaxall, L. Dwyer-nield, A. Bauer, T. Bohlmeyer, A. Malkinson et al., Differential Expression and Localization of the mRNA Binding Proteins, AU-Rich Element mRNA Binding Protein (AUF1) and Hu Antigen R (HuR), in Neoplastic Lung Tissue, Molecular Carcinogenesis, vol.274, issue.2, pp.76-83, 2000.
DOI : 10.1016/0027-5107(94)90245-3

J. Wang, W. Zhao, Y. Guo, B. Zhang, Q. Xie et al., The Expression of RNA-Binding Protein HuR in Non-Small Cell Lung Cancer Correlates with Vascular Endothelial Growth Factor-C Expression and Lymph Node Metastasis, Oncology, vol.76, issue.6, pp.420-429, 2009.
DOI : 10.1159/000216837

J. Wang, B. Wang, J. Bi, and C. Zhang, Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer, Medical Oncology, vol.69, issue.S1, pp.577-585, 2010.
DOI : 10.1158/0008-5472.CAN-09-0371

L. Lauriola, P. Granone, S. Ramella, P. Lanza, and F. Ranelletti, Expression of the RNA-binding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma, Histol. Histopathol. mai, vol.27, issue.5, pp.617-626, 2012.

G. Kim, S. Lim, and Y. Kim, Expression of HuR, COX-2 and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas, Modern Pathology, vol.59, issue.10, pp.1336-1347, 2011.
DOI : 10.1111/j.1365-2559.2007.02629.x

D. Seigneurin and P. Guillaud, Ki-67 antigen, a cell cycle and tumor growth marker], Pathol. Biol. déc, vol.39, issue.10, pp.1020-1028, 1991.

P. Guillaud, S. Du-manoir, and D. Seigneurin, Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7), Anal Cell Pathol. févr, vol.1, issue.1, pp.25-39, 1989.

T. Scholzen and J. Gerdes, The Ki-67 protein: From the known and the unknown, Journal of Cellular Physiology, vol.19, issue.31, pp.311-322, 2000.
DOI : 10.1093/ajcp/110.1.24

E. Luporsi, F. André, F. Spyratos, P. Martin, J. Jacquemier et al., Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Research and Treatment, vol.63, issue.Suppl, pp.895-915, 2012.
DOI : 10.1136/jcp.2010.077578

B. Martin, M. Paesmans, C. Mascaux, T. Berghmans, P. Lothaire et al., Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis, British Journal of Cancer, vol.27, issue.12, pp.2018-2025, 2004.
DOI : 10.1016/S0033-0620(85)80003-7

C. Lee, R. Johnson, J. Wichterman-kouznetsova, R. Guha, M. Ferrer et al., High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them, Methods, vol.57, issue.2, pp.234-248, 2012.
DOI : 10.1016/j.ymeth.2012.03.031

J. Kikuchi, I. Kinoshita, Y. Shimizu, E. Kikuchi, K. Takeda et al., Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer, Lung Cancer, vol.72, issue.2, pp.229-237, 2011.
DOI : 10.1016/j.lungcan.2010.08.020

J. Yang, N. Ramnath, K. Moysich, H. Asch, H. Swede et al., Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer, BMC Cancer, vol.81, issue.24, p.203, 2006.
DOI : 10.1002/(SICI)1097-0215(19990611)81:6<930::AID-IJC15>3.0.CO;2-A

B. Werynska, B. Pula, B. Muszczynska-bernhard, A. Piotrowska, A. Jethon et al., Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer, Anticancer Res. sept, vol.31, issue.9, pp.2833-2839, 2011.

S. Fujioka, K. Shomori, K. Nishihara, K. Yamaga, K. Nosaka et al., Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication, Lung Cancer, vol.65, issue.2, pp.223-229, 2009.
DOI : 10.1016/j.lungcan.2008.11.007

G. Gauchotte, C. Vigouroux, F. Rech, S. Battaglia-hsu, M. Soudant et al., Expression of Minichromosome Maintenance MCM6 Protein in Meningiomas is Strongly Correlated With Histologic Grade and Clinical Outcome, The American Journal of Surgical Pathology, vol.36, issue.2, pp.283-291, 2012.
DOI : 10.1097/PAS.0b013e318235ee03

S. Sassen, E. Miska, and C. Caldas, MicroRNA???implications for cancer, Virchows Archiv, vol.129, issue.10, pp.1-10, 2007.
DOI : 10.1007/s00428-007-0532-2

URL : http://europepmc.org/articles/pmc2151131?pdf=render

S. Hammond, RNAi, microRNAs, and human disease, Cancer Chemotherapy and Pharmacology, vol.75, issue.S1, pp.63-68, 2006.
DOI : 10.1007/s00280-006-0318-2

J. Lu, G. Getz, E. Miska, E. Alvarez-saavedra, J. Lamb et al., MicroRNA expression profiles classify human cancers, Nature, vol.1, issue.7043, pp.834-838, 2005.
DOI : 10.1016/S1535-6108(02)00018-1

P. Guan, Z. Yin, X. Li, W. Wu, and B. Zhou, Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues, Journal of Experimental & Clinical Cancer Research, vol.31, issue.1, p.54, 2012.
DOI : 10.1158/0008-5472.CAN-10-1348

F. Xu, X. Zhang, Y. Lei, X. Liu, Z. Liu et al., Loss of Repression of HuR Translation by miR-16 May Be Responsible for the Elevation of HuR in Human Breast Carcinoma, Journal of Cellular Biochemistry, vol.38, issue.5, pp.727-734, 2010.
DOI : 10.1172/JCI12973

K. Abdelmohsen, S. Srikantan, Y. Kuwano, and M. Gorospe, miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels, Proceedings of the National Academy of Sciences, vol.3, issue.3, pp.20297-20302, 2008.
DOI : 10.1371/journal.pone.0001864

URL : http://www.pnas.org/content/105/51/20297.full.pdf

K. Abdelmohsen, M. Kim, S. Srikantan, E. Mercken, S. Brennan et al., miR-519 suppresses tumor growth by reducing HuR levels, Cell Cycle, vol.9, issue.7, p.1354, 2010.
DOI : 10.4161/cc.9.7.11164

URL : http://www.tandfonline.com/doi/pdf/10.4161/cc.9.7.11164?needAccess=true

A. Navarro, T. Diaz, E. Gallardo, N. Viñolas, R. Marrades et al., Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer, Journal of Surgical Oncology, vol.18, issue.5, pp.411-415, 2011.
DOI : 10.1038/mt.2009.207

H. Peltier and G. Latham, Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues, RNA, vol.14, issue.5, pp.844-852, 2008.
DOI : 10.1261/rna.939908

C. Costantino, A. Witkiewicz, Y. Kuwano, J. Cozzitorto, E. Kennedy et al., The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase, Cancer Research, vol.69, issue.11, pp.4567-4572, 2009.
DOI : 10.1158/0008-5472.CAN-09-0371

N. Bandi, S. Zbinden, M. Gugger, M. Arnold, V. Kocher et al., miR-15a and miR-16 Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non-Small Cell Lung Cancer, Cancer Research, vol.69, issue.13, pp.5553-5559, 2009.
DOI : 10.1158/0008-5472.CAN-08-4277

A. Navarro, T. Diaz, E. Gallardo, N. Viñolas, R. Marrades et al., Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer, Journal of Surgical Oncology, vol.18, issue.5, pp.411-416, 2011.
DOI : 10.1038/mt.2009.207

K. Abdelmohsen and M. Gorospe, Posttranscriptional regulation of cancer traits by HuR, Wiley Interdisciplinary Reviews: RNA, vol.182, issue.Suppl 3, pp.214-229, 2010.
DOI : 10.4049/jimmunol.0900377